About Emedgene
Emedgene is a genomic interpretation software platform that has been acquired by and integrated into Illumina's portfolio of genomics solutions. The company specializes in germline variant interpretation, providing AI-powered tools that help clinical laboratories, genetic counselors, and healthcare providers analyze and interpret genetic variants more efficiently. Emedgene's platform automates the complex process of variant classification, leveraging artificial intelligence and machine learning to accelerate the diagnosis of genetic and rare diseases. The software integrates with next-generation sequencing (NGS) workflows and supports clinical applications in reproductive health, oncology, and genetic disease diagnosis. As part of Illumina's Connected Analytics suite, Emedgene serves genetic testing laboratories, health systems, and research institutions seeking to streamline their genomic interpretation workflows. The platform is designed to reduce the time from sequencing to clinical reporting while maintaining high accuracy in variant classification, supporting the broader mission of making genomic medicine more accessible and actionable in clinical practice.
Clinical Focus
Medical conditions and clinical areas addressed by Emedgene.
Who It Serves
Milestones & Awards
Recent Milestones
Acquired by and integrated into Illumina's Connected Analytics portfolio as part of their genomics software suite
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.